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V3Achieving humoral immunity against human immunodeﬁciency virus (HIV) is a major obstacle in AIDS
vaccine development. Despite eliciting robust humoral responses to HIV, exposed hosts rarely produce
broadly neutralizing antibodies. The present study utilizes simian immunodeﬁciency virus (SIV) to identify
viral epitopes that conferred antibody neutralization to clone SIV/17E-CL, an in vivo variant derived from
neutralization resistant SIVmac239. Neutralization assays using rhesus macaque monoclonal antibodies were
performed on viruses engineered to express single or multiple amino acid mutations. Results identiﬁed a
single amino acid mutation, P334R, in the carboxy-terminal half of the V3 loop as a critical residue that
induced neutralization while retaining normal glycoprotein expression on the surface of the virus.
Furthermore, the R334 residue yielded neutralization sensitivity by antibodies recognizing diverse
conformational and linear epitopes of gp120, suggesting that neutralization phenotype was a consequence
of global structural changes of the envelope protein rather than a speciﬁc site epitope.hool of Medicine, Center for
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Infection of nonhuman primates with simian immunodeﬁciency
virus (SIV) provides a model for studying immune responses
associated with HIV/AIDS in humans (Johnson and Hirsch, 1992).
Both cellular and humoral immune responses have been correlated
with protective immunity against SIV (Clements et al., 1995; Maecker
and Maino, 2003; Paiardini et al., 2008; Sato and Johnson, 2007).
Passive protection studies have further demonstrated that antibodies
can provide protective immunity when present prior to or immedi-
ately preceding HIV or SIV challenge (Haigwood et al., 1996; Lewis
et al., 1993; Mascola et al., 1999, 2003, 2000; Nishimura et al., 2002,
2003; Parren et al., 2001; Van Rompay et al., 1998). Unfortunately,
these protective antibodies are infrequently observed in exposed
hosts and are predominantly directed to intricate, conformationally
dependent epitopes of the SIV envelope (env) proteins in regions with
a propensity for mutation and subsequent immune evasion (Coleet al., 2001; Haigwood et al., 1992; Javaherian et al., 1994, 1992; Sato
and Johnson, 2007). Therefore, identifying viral epitopes that play a
role in antibody neutralization is important for our understanding of
the immunogenic properties of SIV and HIV and will serve to enhance
vaccine development.
Some limited HIV and SIV antibody-neutralizing epitopes have
been identiﬁed within the viral env gene (Pantophlet and Burton,
2006; Sato and Johnson, 2007). The HIV and SIV env gene produces a
polyprotein (gp160) that is extensivelymodiﬁed by post-translational
polysaccharide addition and is cleaved by host protease (furin) into
two separate glycoproteins, gp120 [surface subunit (SU)] and gp41
[transmembrane subunit (TM)] (Luciw, 1996). On the surface of the
virus, complete env complexes are comprised of a trimer of
noncovalently linked heterodimers of gp120 and gp41. The role of
these proteins in virus attachment and entry has been well
characterized (Wyatt and Sodroski, 1998). Gp120 is involved with
CD4 and co-receptor recognition and binding, while gp41 is
responsible for forming the env trimer and mediating cell–virus
fusion. Less well known is how neutralizing antibody responses to SIV
and HIV are directed against the viral epitopes of the env proteins.
Neutralizing antibody responses against SIV have been demonstrated
to be associated with the gp41 cytoplasmic tail, ecto, and transmem-
brane domains (Bonavia et al., 2005; Overholser et al., 2005; Puffer
et al., 2004). Within gp120, V1/V2 (Johnson et al., 2002, 2003; Puffer
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et al., 2004), and V4 regions (Choi et al., 1994; Kinsey et al., 1996)
have also demonstrated signiﬁcant roles in affecting virus neutrali-
zation by antibodies. Identifying and characterizing these determi-
nants of neutralization in SIV have increased our understanding of the
antigenic qualities of envelope proteins. However, more information
is required to solve the precise molecular structure and antigenic
qualities of these proteins.
The present study was designed to identify the amino acid
residues within the env gene that contribute to the antibody
neutralization phenotype of SIV/17E-CL, a naturally derived clone
of neutralization-resistant SIVmac239 that acquired nine amino acid
mutations in gp120 (V67M, K141R, T158A, K176N, Q217K, M309I,
P334R, K340R, and G382R) (Anderson et al., 1993; Regier and
Desrosiers, 1990; Sharma et al., 1992). Our earlier investigations
using surface plasmon resonance (SPR) determined that differences
in association and dissociation kinetic rates of antibody with
SIV/17E-CL env proteins were causative for the neutralization
phenotype (Steckbeck et al., 2005). However, the region of the viral
protein or the epitope(s) involved remained unknown. Here we
investigated antibody-mediated neutralization in vitro with viruses
engineered to express amino acid residues from SIV/17E-CL gp120Fig. 1. Design and characterization of SIV mutant viruses. Mutations in SIV/17E-CL are distrib
cloning strategy utilizes the Bpu10I restriction site, 5′ to the start codon of gp120, and the Nh
infectious virus in vitro that activated LTR-luc expression in the TZM-bl. Viral titer stocks rawithin the SIVmac239 backbone. Results from these studies described
a novel V3 epitope that conferred neutralization of SIVmac239 by
monoclonal antibodies to both linear and conformational epitopes,
suggesting that neutralization phenotype was the consequence of
global structural changes of the env protein complex.
Results
Synthesis of mutant viruses
The envelope gene of SIV/17E-CL differs from SIVmac239 by 9
amino acids in gp120 (V67M, K141R, T158A, K176N, Q217K, M309I,
P334R, K340R, and G382R), see Fig. 1 (Anderson et al., 1993). Single
and multiple rounds of site-directed mutagenesis (see Materials and
methods) were used to generate amino acid mutations in the gp120
env SIVmac239 backbone according to a scheme that represents
mutation sets in and around the V1/V2, or V3 regions of SIV/17E-CL
(Fig. 1). Viral stocks were generated from recombinant virus
constructs in mammalian tissues as described in the Materials and
methods section. Synthesis of infectious virus was veriﬁed from every
engineered construct and yielded viral stock titers ranging from 102 to
105 TCID50 per milliliter (data not shown).uted throughout the gp120 env gene and cluster around the V1/V2 and V3 regions. The
e1 restriction site on the 3′ end of the ectodomain of gp41. All mutant constructs created
nged from 102 to 105 TCID50 per milliliter.
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Previous reports suggest that mutations in SIV gp120 that reduce
envelope incorporation into viral membranes and/or increase env
shedding from the viral membrane result in enhanced sensitivity to
antibody-mediated neutralization (Klasse and Moore, 1996; Yuste et
al., 2005). We previously demonstrated that SIV/17E-CL env expres-
sion is similar to SIVmac239 and is therefore not a factor for
neutralization (Steckbeck et al., 2005). To determine whether the
mutant viruses studied here displayed altered env expression, we
assessed the quantity of gp120 present in mutant viruses. Fig. 2a
demonstrated that with the exception of 239-A158, 239-NK-IRRR,
239-NK, and 239-N176, all mutant viruses expressed levels of gp120
env similar to SIVmac239. To measure the level of gp120 env in each
mutant clone, band densities from duplicate experiments were
determined for gp120 env and p27gag and the ratios were compared
to the parental virus, SIVmac239. Using this semiquantitative analysis,
four mutant viruses (239-A158, 239-NKIRRR, 239-NK, and 239-N176)
displayed signiﬁcant decreases in gp120 expression (35%, 4.9%, 17%,
and 11%, respectively) (Fig. 2b). Interestingly, while 239-A158
displayed reduced gp120 expression, 239-MRA and 239-MRA-IRRR,
which also contained the T158A mutation, did not express a reduced
gp120 env phenotype. So, the signiﬁcant reduction of env by T158A
only occurred when T158A was expressed alone (239-A158). Fig. 2b
also demonstrated that mutant viruses with the K176N mutation
(239-NKIRRR, 239-NK and 239-N176) expressed signiﬁcantly lower
levels of gp120 env. Thus, the analysis of gp120 expression showed
that env content was unperturbed in most mutants and signiﬁcant
variability was limited to few mutants with distinct point mutations.Fig. 2. Analysis of gp120 expression in mutant viruses. (a) Virus supernatants were pelleted
structural protein p27gag (MAb 2F12). (b) Band densities were determined, and the gp120/
mean gp120/p27gag ratio (±SD) compared to SIVmac239 from two independent experimLastly, the immunoblot analysis revealed one further observation.
Fig. 2a showed that gp120 env from mutants with the A158 residue
(239-MRA, 239-A158, and 239-MRA-IRRR) resolved at a lower
molecular weight than SIVmac239 and mutants with T158. This
migration pattern of the env proteins would suggest that the T158A
mutation resulted in a loss of an N-linked glycosylation residue, as
expected by the change in amino acid sequence, N-C-T→N-C-A.
Analysis of V1/V2 region residues for neutralization sensitivity to
monoclonal antibodies
Each mutant virus was examined for neutralization sensitivity
using the TZM-bl assay (Steckbeck et al., 2005). Neutralization studies
were divided into study groups of mutants according to region and are
summarized in Fig. 1. Data from V1 region mutants showed that the
239-MRA virus (mutations V67M, K141R and T158A) was not
neutralized by MAb at the highest concentration (10 μg/ml) (Table
2). The 239-M67 (V67M) and 239-R141 (K141R) mutants alone were
also not sensitive to neutralization (Table 2). However, the 239-A158
mutant (T158A) yielded a clone that was partially sensitive to
neutralization by MAbs that recognize epitopes on the carboxy-
terminal half of gp120. Four of the eight neutralizing antibodies
yielded mean IC50 values (0.64–0.037 μg/ml, Table 2) within one
log10 deviation from the IC50 values observed in SIV/17E-CL (Table 2).
Interestingly, the 239-NKIRRR mutant that contains the V2 and V3
mutations and none of the V1 mutations demonstrated a neutraliza-
tion proﬁle more comparable to SIV/17E-CL (Table 2) with IC50 values
ranging from 0.39 to 0.003 μg/ml (Table 2). Therefore, the single point
mutation T158A in V1 conferred partial neutralization sensitivity in, and denatured viral proteins were immunodetected for gp120 env (MAb 3.11H) and
p27gag ratio of each mutant was calculated. The data reported are the percent change in
ents.
Table 1
Monoclonal antibody phenotypes: epitope speciﬁcity and SIV neutralization.
MAb Binding groupa Putative binding domainb Epitope conformationc Neutralizing antibody titer (μg/ml)d
SIV/17E-CL SIVmac239
3.8E I N′ terminus Conformational N25 N25
3.10A II V1 Linear N25 N25
5.5B III V2 Linear N25 N25
3.11H IV V3-cys loop Linear 0.070 N25
1.11A V CCR5 bs Conformational 0.125 N25
4.7A V CCR5 bs Conformational 0.021 N25
3.11E VIa CCR5 bs Conformational 0.038 N25
3.2C VIb V4 Conformational 0.015 N25
E31 VIb V4 Conformational 0.039 N25
1.10A VII V4 Conformational 0.009 N25
C26 VII V4 Conformational 0.006 N25
3B3 VIII Unknown Conformational N25 N25
a Competition groups were previously deﬁned by cross-competition ELISA (Cole et al., 2001).
b Putative binding domains are based on previously published data (Cole et al., 2001).
c Epitope conformation was previously determined by reducing/nonreducing immunoblot (Cole et al., 2001).
d Neutralization antibody titers were previously assayed and reported as the concentration of MAb that inhibited 50% infection (IC50) using the TZM-bl assay (Steckbeck et al., 2005).
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neutralization.
Next, mutations in the V2 regionwere examined. The 239-NK virus
containing both the K176N and Q217K mutations was partially
sensitive to neutralization (Table 2), albeit to a lesser degree than SIV/
17E-CL (Table 2). Only two of the eight neutralizing antibodies
displayed IC50 values within a log10 deviation of SIV/17E-CL. Further
analysis of the V2 mutations was performed with clones 239-N176
(K176N) and 239-K217 (Q217K). 239-N176 was sensitive to antibody
neutralization (IC50 values, 1.11 to 0.031 μg/ml), while 239-K217 was
not neutralized by the antibodies tested (Table 2). Clone 239-MRA-
IRRR lacking the V2 region mutations but containing the V1 and V3
mutations was more sensitive to neutralization than the 239-NK virus
(Table 2), with IC50 values ranging from 0.67 to 0.026 μg/ml.
Therefore, the data of the V2 region analysis showed that the K176N
mutation was sufﬁcient to confer partial neutralization in SIV/17E-CL,
but that the V3 region contained factors for neutralization as well.
Analysis of V3 region residues for neutralization sensitivity to
monoclonal antibodies
Lastly, we evaluated mutations in and around the V3 region
(M309I, P334R, K340R, and G382R) for neutralization sensitivity.
Mutant clone 239-IRRR, expressing all four point mutations around
V3, showed IC50 values equivalent to SIV/17E-CL, ranging from 0.31 to
0.006 μg/ml (Table 3). To elucidate the critical neutralizing mutations
in V3, additional single point mutants were generated and assayed for
neutralization. The 239-I309 (M309I), 239-R340 (K340R), and 239-Table 2
Neutralization phenotype resulting from V1 and V2 mutations.a
Monoclonal
antibody
Binding
domain
Mac239 17E-CL V1
239-
MRA
239-
M67
239-
R141
23
3.8E N′ terminus N10 N10 N10 N10 N10 N1
3.10A V1 N10 N10 N10 N10 N10 N1
5.5B V2 N10 N10 N10 N10 N10 N1
3.11H V3-cys loop N10 0.046 (0.02) N10 N10 8.30 (2.4) 0.
1.11A CCR5 bs N10 0.075 (0.05) N10 N10 N10 0.
4.7A CCR5 bs N10 0.016 (0.01) N10 N10 N10 0.
3.11E CCR5 bs N10 0.024 (0.02) N10 N10 8.65 (1.9) 0.
3.2C V4 N10 0.022 (0.01) N10 N10 N10 0.
E31 V4 N10 0.029 (0.02) N10 N10 N10 0.
1.10A V4 N10 0.005 (0.004) N10 N10 5.25 (3.7) 0.
C26 V4 N10 0.004 (0.003) N10 N10 N10 0.
3B3 Unknown N10 N10 N10 N10 N10 N1
Values in bold type represent mean IC50 values that do not exceed 1 log10 variance from th
a IC50 neutralization titers are reported as the mean concentration of MAb (μg/ml) (±SDR382 (G382R) mutants were resistant to neutralization by all MAbs
tested (Table 3). Of these clones, only 239-R334 (P334R) demon-
strated a neutralization phenotype equivalent to 239-IRRR and SIV/
17E-CL (Table 3). To determine the contribution of the neighboring
mutations that also introduced an arginine (R) in and around V3
(K340R and G382R), combination mutant clones were assayed for
neutralization. The data from clones 239-RRR, 239-R334R340, and
239-R340R382 reinforced the observation of the P334R mutation as
the neutralizing determinant, as only those clones containing the
R334 residue (239-RRR and 239-R334R340) yielded a neutralization
phenotype equal to 239-IRRR (Table 3). Furthermore, all mutant
clones assayed that contained P334R (239-NKIRRR, 239-MRA-IRRR,
239-IRRR, 239-R334, 239-RRR, and 239-R334R340) were neutraliza-
tion sensitive (Tables 2 and 3) with IC50 values for MAbs that were
equivalent to SIV/17E-CL.
Discussion
This study analyzed the antibody neutralization phenotypes result-
ing from single and multiple point mutations in SIVmac239 gp120
representingmutationsderived fromSIV/17E-CL. Using a broadpanel of
rhesus MAbs with linear and conformational epitopes to multiple
domains throughout SIV gp120, we sought to identify the mutation(s)
responsible for inducing antibody mediated neutralization seen in SIV/
17E-CL. The ﬁrst mutation identiﬁed, T158A, only inﬂuenced neutral-
ization when expressed alone, as seen in virus 239-A158 (Table 2).
Interestingly, the mutation of threonine 158 to alanine removes a
potentialN-linked glycosylation site fromSIVmac239(g6)by disruptingV2
9-A158 239-NKIRRR 239-NK 239-N176 239-
K217
239-MRA-
IRRR
0 N10 N10 N10 N10 N10
0 6.43 (0.81) N10 N10 N10 N10
0 1.18 (0.45) N10 N10 N10 N10
510 (0.41) 0.028 (0.02) 1.01 (0.43) 1.11 (1.1) N10 0.260 (0.18)
143 (0.14) 0.039 (0.01) 0.215 (0.01) 0.857 (0.90) N10 0.673 (0.31)
300 (0.27) 0.017 (0.01) 0.530 (0.32) 0.233 (0.15) N10 0.300 (0.16)
640 (0.65) 0.010 (0.01) 1.24 (1.1) 0.154 (0.19) N10 0.220 (0.07)
225 (0.22) 0.029 (0.01) 0.273 (0.16) 0.331 (0.29) N10 0.133 (0.07)
175 (0.02) 0.023 (0.01) 0.195 (0.02) 0.042 (0.01) N10 0.520 (0.28)
026 (0.02) 0.002 (0.001) 0.084 (0.01) 0.029 (0.03) 5.49 (4.1) 0.033 (0.01)
037 (0.003) 0.003 (0.001) 0.089 (0.03) 0.031 (0.04) N10 0.026 (0.01)
0 N10 N10 N10 N10 N10
e IC50 of SIV/17E-CL.
) from at least two independent experiments.
Table 3
Neutralization phenotype resulting from V3 mutations.a
Monoclonal
antibody
Binding
domain
Mac239 17E-CL V3
239-IRRR 239-I309 239-R334 239-R340 239-R382 239-RRR 239-R334R340 239-R340R382
3.8E N′ terminus N10 N10 N10 N10 N10 N10 N10 N10 N10 N10
3.10A V1 N10 N10 3.58 (0.39) N10 6.43 (2.8) N10 N10 7.13 (4.9) N10 N10
5.5B V2 N10 N10 9.08 (1.85) N10 5.58 (4.7) 8.90 (2.2) N10 N10 N10 N10
3.11H V3-cys loop N10 0.046 (0.02) 0.313 (0.38) N10 0.111 (0.06) 8.98 (2.0) 9.36 (1.1) 0.086 (0.06) 0.435 (0.50) N10
1.11A CCR5 bs N10 0.075 (0.05) 0.228 (0.24) N10 0.110 (0.07) N10 N10 0.069 (0.03) 0.200 (0.12) N10
4.7A CCR5 bs N10 0.016 (0.01) 0.056 (0.07) N10 0.051 (0.03) N10 N10 0.042 (0.02) 0.075 (0.02) N10
3.11E CCR5 bs N10 0.024 (0.02) 0.059 (0.07) N10 0.062 (0.04) 7.85 (4.3) 7.68 (2.7) 0.050 (0.02) 0.072 (0.05) N10
3.2C V4 N10 0.022 (0.01) 0.014 (0.02) N10 0.048 (0.03) 7.10 (3.6) 7.76 (4.4) 0.016 (0.01) 0.060 (0.04) N10
E31 V4 N10 0.029 (0.02) 0.010 (0.13) N10 0.101 (0.03) N10 N10 0.161 (0.15) 0.050 (0.01) N10
1.10A V4 N10 0.005 (0.004) 0.005 (0.004) N10 0.004 (0.002) 6.73 (2.8) 7.08 (3.6) 0.004 (0.002) 0.023 (0.03) 7.80 (3.8)
C26 V4 N10 0.004 (0.003) 0.006 (0.007) N10 0.004 (0.004) 7.85 (4.3) 9.06 (1.6) 0.006 (0.002) 0.010 (0.01) N10
3B3 Unknown N10 N10 N10 N10 N10 N10 N10 N10 N10 N10
Values in bold type represent mean IC50 values that do not exceed 1 log10 variance from the IC50 of SIV/17E-CL.
a IC50 neutralization titers are reported as the mean concentration of MAb (μg/ml) (±S.D.) from at least two independent experiments.
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Previous research suggests that the carbohydrates around V1/V2 and
V3 shield epitopes on env because removal of glycosylation sites in SIV
often enhances antibody neutralization (Chackerian, Rudensey, and
Overbaugh, 1997; Cole et al., 2004; Reitter and Desrosiers, 1998; Reitter
et al., 1998). In our study, the T158A Δg6 mutation induced a
neutralizing phenotype when expressed alone (239-A158) but showed
no effectwhen othermutationswere expressed in cis, 239-MRA (V67M,
K141R, and T158A). A more signiﬁcant observation of the 239-A158
(T158A) mutant was a signiﬁcant reduction in gp120 env/p27gag ratio
compared to SIVmac239 (Fig. 2b). Reduced envelope content in the
virion has been correlated with neutralization sensitivity of HIV and SIV
(Klasse and Moore, 1996; Yuste et al., 2005). Therefore, reduced env
protein expression would explain the neutralization sensitivity of the
239-A158 clone, yet does not dictate the neutralization phenotype of
SIV/17E-CL, which does not have lowered env expression.
Next, a K176N mutation amino-terminal to V2 was observed to
inducemonoclonal antibodymediated neutralization in vitro, albeit to
a lesser degree than SIV/17E-CL (Tables 1 and 2). As reported
previously, V1/V2 plays a role in neutralization, given that mutations
and deletions of V1/V2 induce a neutralizing phenotype (Johnson et
al., 2002, 2003; Puffer et al., 2004). Neutralization sensitivity has been
reported for SIVmac316 that expresses a mutation at amino acid 176
in gp120 (Johnson et al., 2003; Means et al., 2001). Furthermore, the
MERT cluster of mutations (V67M, K176E, G382R K573T) is
implicated in the macrophage tropic phenotype associated with
SIVmac316 (Mori et al., 1992). Macrophage tropism is often
associated with antibody neutralization sensitivity in SIV (Means et
al., 2001; Puffer et al., 2002; Rudensey et al., 1998). Indeed, SIV/17E-
CL is macrophage tropic (Mankowski et al., 1997); however, the V67M
and G382R mutations had no effect on neutralization sensitivity in
this study (Tables 2 and 3). More importantly the K176N mutation
yielded signiﬁcant reductions in envelope expression (Fig. 2). As may
be the case for the T158A mutation, the atypically lowered expression
of the glycoproteins on the viral membrane of the SIV K176N mutant
induced the observed antibody neutralization phenotype.
In this study, the most signiﬁcant changes in antibody mediated
neutralization were observed in the carboxy-terminal portion of the V3
loop at residue 334 (Table 3). All mutants assayed that contained R334
(239-NKIRRR, 239-MRA-IRRR, 239-IRRR, 239-R334, 239-RRR, and 239-
R334R340) were neutralized by MAbs at concentrations equivalent to
SIV/17E-CL while retaining normal protein expression of env (Fig. 2).
Although impressive, it is not so surprising given the documented
importance that HIV and SIV V3 has in regard to viral tropism and
neutralization phenotypes (Hartley et al., 2005). Evidence thus far
suggests that the V3 loop may be split into two domains each with a
different role in determining phenotype. The amino-terminal portion is
suggested to directly interact with neutralizing antibodies, while thecarboxy-terminal portion is weakly or non-immunogenic and may
interact with other domains of the gp120 monomer (Benichou et al.,
1993; Huang et al., 2005; McBride et al., 1993;Miller et al., 1992; Palker
et al., 1996; Pohlmannet al., 2004; Rosen et al., 2005; Rosen et al., 2008).
Changes in the carboxy-terminal domain of V3 are suspected to
inﬂuence phenotype via structural changes of the individualmonomers
or the complete trimer (Huang et al., 2005; Rosen et al., 2008; Rosen et
al., 2006). Our data support this theory in part because the neutralizing
phenotype obtained by the P334Rmutationwas apparent not only for a
V3-binding antibody (3.11H) but for the entire panel of MAbs
recognizing both linear and conformational epitopes clustered through-
out the gp120 molecule (Table 3).
One particular model in HIV could explain structure changes
associated with R334. The “11/25” rule states that in HIV-1-negative/
neutral charges at residues 11 or 25 in the V3 loop confer CCR5 co-
receptor usage and macrophage tropism, while positive charges yield
CXCR4 co-receptor usage and T-lymphocyte or dual tropism phenotype
(De Jong et al., 1992; Fouchier et al., 1992; Resch et al., 2001). The
corresponding amino acids in T-lymphotrophic SIVmac239 V3 are 11
(P306) and 25 (P334). Interestingly, Rosen et al. (2008) recently
demonstrated that the 25th amino acid in HIV-1 V3, residue 322,
displays electrostatic interactionwith residue 440 in the C4domain. The
440 residue in C4 was mapped as the second amino acid following a
conserved YAPP domain, which is also present in SIVmac as a YLPP
domain. Interestingly, the second amino acid carboxy-terminal to this
domain in SIV is a negatively charge glutamic acid E454. If SIV structure
is homologous toHIV-1, the R334 and E454would theoretically interact
with electrostatic attraction and yield structure and phenotype of
macrophage tropic viruses. Indeed, studies of SIV V3 mutations found
that changing P334 to uncharged amino acids leucine or glutamine did
not confer macrophage tropism in SIVmac239 (Kirchhoff et al., 1994;
Pohlmann et al., 2004), yet SIV/17E-CL (R334) is a macrophage tropic
virus (Mankowski et al., 1997). Therefore, it is feasible that the 11/25
rule for positivity applies to HIV-1 but could more broadly reﬂect the
necessity for position speciﬁc electrostatic interactions between V3 and
other regions of SIV gp120, such as V4.
This study identiﬁed the P334R mutation in the C′-terminal
portion of the V3 loop to be the main determinant of neutralization
in SIV/17E-CL. Since this residue affected neutralization by MAbs
recognizing diverse conformational and linear epitopes in gp120 and
that the V3 region has been observed to be associated with viral
tropism and neutralization phenotypes, it is likely that the neutral-
ization-sensitive phenotype of SIV/17E-CL is a result of the structural
changes of the envelope protein elicited by the P334Rmutation. Given
the currently limited data describing V3 structure within the context
of gp41/gp120 trimers, this report supports the importance of further
studies on the V3 region to assist in developing effective therapeutics
and preventative strategies against HIV AIDS.
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Cells
293T cells and SIV-permissive TZM-bl cells (Wei et al., 2002),
which express CD4, CCR5, CXCR4, and HIV/SIV-inducible ﬁreﬂy
luciferase, were maintained in Dulbecco's modiﬁed Eagle's medium
(DMEM) media (Gibco-Invotrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA).
Construction of mutant proviruses
Previously characterized provirus constructs SIVmac239 (Regier
and Desrosiers, 1990) and SIVmac17E-CL (Anderson et al., 1993) were
digested with Nhe1 and Bpu10I to isolate the encoding region of gp120
andaportion of the ectodomainof gp41 (Fig. 1). This regionwas ligated
with homologous restriction sites into a CMV promoter expression
vector, TR600 (Bower et al., 2004), using T4 DNA ligase (New England
Biolabs, Ipswich, MA) and recombinant DNAwas synthesized in DH5α
competent cells. The wild-type gp120 env sequences were mutagen-
ized using the QuickChange XL Site Directed Mutagenesis kit
(Stratagene, La Jolla, CA) according to manufacturer's protocol and
sequence speciﬁc primers. The mutant env constructs were ligated
back into the SIV proviral backbone using Nhe1 and Bpu10I restriction
sites and T4 DNA ligase and propagated in Stbl2 competent cells
(Invitrogen, Carlsbad, CA). Transfection grade plasmids clones were
veriﬁed by DNA sequencing at the University of Pittsburgh Genomics
and Proteomics Core laboratory (Pittsburgh, PA) using an ABI 3730xl
DNA analyzer (Applied Biosystems, Foster City, CA).
Production of viruses
SIVmac239, SIV/17E-CL, and mutant proviral DNA were transiently
transfected as previously described (Bower et al., 2004). Brieﬂy, 8 μg of
proviral DNA was conjugated with 24 μl Lipofectamine 2000 (Invitro-
gen) in Opti-MEM media (Invitrogen) and incubated with 6–7×106
293T cells for 5 h at 37 °C. The media was replaced with 10 ml of fresh
Opti-MEM and the cultures were incubated an additional 48 h at 37 °C.
Cell free supernatants were harvested and frozen at −80°C prior to
experimental analysis. Virus titer was determined by serially diluting
viral supernatants in DMEMmedia and culturingwith TZM-bl cells (104
cells per well) in 96-well plates (BD-Falcon, San Jose, CA). Following an
incubation of 48 h, supernatantswere removed and the cells were lysed
with 50 μl cell lysis buffer (Promega, Madison, WI) for 15 min at room
temperature. Lysates (40 μl) were transferred to white luminescence
plates (USA Scientiﬁc,Ocala, Fl) and assayed for luciferase productionon
a Lmax II luminometer (Molecular Devices, Union City, CA)with 25 μl of
Luciferase Assay Substrate (Promega) per well. The TCID50 was
determined using the Reed and Meunch method (Poli and Fauci,
2004),with apositive cutoff value2.5 times that of thenegative samples.
Virus neutralization determination
MAbs (Table 1) were serially diluted 5-fold in DMEM containing
10% FBS in sterile 96-well V-bottom plates (Sarstedt, Newton, NC) for
a ﬁnal assay concentration range of 10–0.00013 μg/ml. Virus was
diluted in DMEM with 10% FBS to yield an MOI of 0.01, mixed with
diluted MAb, and pre-incubated 1 h at 37 °C. The virus–MAb mixture
was added to TZM-bl cells (104 cells per well) in 96-well plates (BD-
Falcon) and cultured in the presence of 20 μg/ml DEAE-Dextran
(Amersham Biosciences, Piscataway, NJ) for 48 h. SIV infection was
assayed by luciferase production as described above. Neutralizing
titers are reported as the IC50, the MAb concentration (μg/ml) that
neutralized 50% of the virus infection, using the method of Karber
(1931). All values represent the averages of at least two independent
experiments assayed in duplicate.Western blot analysis
To quantitate envelope content of each SIV mutant, viral super-
natants were pelleted over a 10% glycerol cushion at 19,000×g for
1.5 h at 4 °C, denatured by boiling in reducing buffer and resolved by
SDS-PAGE using Tris–HCl 5 and 12.5% gels (Bio-Rad, Hercules, CA).
Viral proteins were transferred to polyvinylidine diﬂuoride mem-
brane and probed for gp120 env using a MAb directed against a linear
epitope in V3 not affected by the mutations in this study [3.11H (Cole
et al., 2001)] and p27gag using MAb 2F12 (NIH AIDS Research and
Reference Reagent Program). Band densities of gp120 env and p27gag
were determined using ImageJ software (National Institutes of Health,
Bethesda, MD). Each immunoblot contained a positive control of
SIVmac239, thus allowing for calculations of the gp120/p27gag ratio
for each mutant virus in relation to the parental strain SIVmac239.
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